Table 1.
Summary of included patients
| N (%) | Mean (range) | |
|---|---|---|
| Patients’ characteristics | ||
| Total number of patients | 27 | |
| Male | 19 (70.3%) | |
| Female | 8 (29.7%) | |
| Age (years) | 65 (39–85) | |
| Height (cm) | 178 (160–196) | |
| Weight (kg) | 78 (49–105) | |
| BMI (kg/m2) | 25 (18–32) | |
| ALAT (U/L) | 46 (14–202) | |
| ASAT (U/L) | 51 (14–449) | |
| γ-GT (U/L) | 57 (11–563) | |
| Bil (μmol/L) | 8 (3–21) | |
| Cr (μmol/L) | 96 (50–183) | |
| CrCL (mL/min) | 70 (31–121) | |
| Disease characteristics | ||
| WHO performance score | ||
| 0 | 9 (33.3%) | |
| 1 | 11 (40.7%) | |
| >1 | 7 (26.0%) | |
| Previous systemic therapy* | ||
| Sunitinib | 4 (11.4%) | |
| Pazopanib | 15 (42.9%) | |
| Nivolumab (± ipilimumab) | 12 (34.3%) | |
| Everolimus | 1 (2.9%) | |
| No previous system therapy | 3 (8.5%) | |
| Prognosis group | ||
| Favorable | 2 (7.4%) | |
| Intermediate | 17 (63.0%) | |
| Poor | 5 (18.5%) | |
| Unknown | 3 (11.1%) | |
| Cabozantinib dosing | ||
| Cabozantinib dose (mg, QD) | 40 (20–60) | |
| Cabozantinib start dose (mg, QD) |
20 mg: 4 (15%) 40 mg: 10 (37%) 60 mg: 13 (48%) |
|
| Cabozantinib last dose (mg, QD) |
20 mg: 5 (19%) 40 mg: 16 (60%) 60 mg: 6 (21%) |
|
| Cabozantinib treatment days (days) | 75 (11–552) | |
| Pharmacokinetic data | ||
| Total number of observations | 75 | |
| Total number of trough concentrations | 36 (48%) | |
| Number of observations per patient | 2 (1–10) | |
| Observed cabozantinib concentration (ng/mL) | 603 (135–1471) | |
| Trough cabozantinib concentration (ng/mL) | 632 (308–1134) | |
γ-GT gamma-glutamyltransferase, ALAT alanine aminotransferase, ASAT aspartate aminotransferase, Bil bilirubin, BMI body mass index, CrCL creatine clearance, Cr creatinine, QD once daily, WHO World Health Organization
*One patient may have several previous system therapies